Market Cap
$1.9B
XNCR
Xencor Inc
$24.71 ▼ -0.24%
Prev close $24.77Market cap$1.9B
ConsensusStrong Buy
12-mo target$31.42 (+27.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)24 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on XNCR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (85%)
Inst. Holders
50 funds
Inst. Value
$1.1B
Inst. Activity
24 buys / 14 sells
Insider Activity
$0.00 buy / $820.3K sell
Insider Net $
-$820.3K
SEC Reports
10
Price chart 30d -8.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Aug 6, 2026 SEC Short Volume: XNCR — 83.2% short (0.7M / 0.9M)
Short: 714,599 | Exempt: 0 | TRF Vol: 858,554 | Short Ratio: 83.2% | Off-exchange volume (dark pool
Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consensus), a significant b
8-K — Impact 7/10
Four Xencor Inc directors sold shares totaling $290K on June 15, 2026, all at $12.31 per share. The cluster represents o
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC — TRIM
2,215,690 shares ($35.7M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
968,778 shares ($15.6M)
Jun 18, 2026 Insider
Feigal Ellen sold 6,843 shares
Director @ $13.06 ($89.4K)
Jun 16, 2026 Insider
Feigal Ellen was granted 20,604 shares
Director
Jun 16, 2026 Insider
Feigal Ellen was granted 10,302 shares
Director
Analyst ratings buy % -5.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
85% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | Truist Securities | REITERATE | Buy | 55% |
| Sep 21, 2026 | B of A Securities | MAINTAIN | Neutral | 54% |
| Sep 11, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 3, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Sep 1, 2026 | Raymond James | MAINTAIN | Strong Buy | 54% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 6, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Aug 6, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jul 30, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jul 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Aug 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Jul 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Jun 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Apr 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Mar 1, 2026 | 6 | 12 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 6 | 12 | 2 | 0 | 0 | 90% |
Price targets
Where 12 covering analysts think XNCR trades over the next 12 months.
$31.42 +27.1% upside Strong Buy
Current$24.71 Low$20.00 Median$30.00 High$46.00 12 analysts
$20.00$46.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 2 bearish, 0 mixed, 5 neutral · avg impact 4.8/10.
BULLISH8-K7/10
Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consens
Aug 6, 2026
NEUTRALCLUSTER2/10
Four Xencor Inc directors sold shares totaling $290K on June 15, 2026, all at $12.31 per share. The
Jul 8, 2026
NEUTRAL1442/10
Director Alan Bruce Montgomery filed a Form 144 notice of intent to sell 5,064 shares of Xencor Inc
Jun 15, 2026
NEUTRAL1442/10
Director Richard J. Ranieri filed a Form 144 to sell 5,474 shares of Xencor Inc (XNCR) worth approxi
Jun 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: XNCR — 83.2% short (0.7M / 0.9M)
Short: 714,599 | Exempt: 0 | TRF Vol: 858,554 | Short Ratio: 83.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: XNCR — 59.0% short (0.3M / 0.6M)
Short: 340,270 | Exempt: 0 | TRF Vol: 576,608 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: XNCR — 81.9% short (0.5M / 0.6M)
Short: 511,051 | Exempt: 0 | TRF Vol: 623,896 | Short Ratio: 81.9% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
Clinical Trial
XmAb20717 in Advanced Biliary Tract Cancers
Phase Phase 2 — COMPLETED
Sep 21, 2026
short_volume
Short Volume: XNCR — 72.6% short (0.4M / 0.6M)
Short: 399,330 | Exempt: 0 | TRF Vol: 550,030 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.40 | $-1.21–$0.22 | -395.8% | -22.9% | 5↑ 0↓ | $0.1B | 12 |
| Next Q | $-0.82 | $-1.26–$-0.10 | -809.9% | -5.7% | 2↑ 3↓ | $0.0B | 12 |
| Current FY | $-3.15 | $-4.47–$-1.87 | -154.1% | -1.2% | 9↑ 2↓ | $0.1B | 12 |
| Next FY | $-3.56 | $-5.00–$-2.18 | -12.8% | -1.9% | 5↑ 6↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.397 | — |
| 7d ago | $-0.397 | — |
| 30d ago | $-0.323 | -0.074 |
| 60d ago | $-0.833 | +0.437 |
| 90d ago | $-0.821 | +0.424 |
Institutional ownership
Which big funds own XNCR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.1B total value (66,479,542 shares) as of 2026-Q2. Top holders: BlackRock,, PRIMECAP, RTW. Net buying activity: 24 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 13,651,261 | $219.8M | 20.5% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 10,181,322 | $163.9M | 15.3% | — |
| RTW INVESTMENTS, LP | 6,777,461 | $109.1M | 10.2% | — |
| RA CAPITAL MANAGEMENT, L.P. | 5,274,274 | $84.9M | 7.9% | NEW |
| STATE STREET CORP | 4,954,016 | $79.8M | 7.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,278,802 | $52.8M | 4.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,215,690 | $35.7M | 3.3% | TRIM -36.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,920,859 | $30.9M | 2.9% | — |
| MORGAN STANLEY | 1,752,556 | $28.2M | 2.6% | — |
| UBS Group AG | 1,306,174 | $21.0M | 2.0% | ADD +69.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | 3,500,342 | 2,215,690 | -36.7% | $35.7M |
| GOLDMAN SACHS GROUP INC | ADD | 763,793 | 968,778 | +26.8% | $15.6M |
| MILLENNIUM MANAGEMENT LLC | ADD | 609,788 | 853,677 | +40.0% | $13.7M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | DOUBLED | 121,342 | 382,094 | +214.9% | $6.2M |
| Hudson Bay Capital Management LP | TRIM | 487,320 | 210,000 | -56.9% | $3.4M |
| CITADEL ADVISORS LLC | TRIM | 377,699 | 190,826 | -49.5% | $3.1M |
| CITIGROUP INC | ADD | 104,299 | 167,189 | +60.3% | $2.7M |
| Trexquant Investment LP | DOUBLED | 44,491 | 144,555 | +224.9% | $2.3M |
| Jump Financial, LLC | DOUBLED | 10,531 | 131,000 | +1143.9% | $2.1M |
| HSBC HOLDINGS PLC | DOUBLED | 58,579 | 125,482 | +114.2% | $2.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 29 transactions. Net -$820.3K — $0.00 bought, $820.3K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Feigal Ellen | Director | SELL | 6,843 | $13.06 | $89.4K |
| Jun 16, 2026 | Feigal Ellen | Director | AWARD | 20,604 | — | — |
| Jun 16, 2026 | Feigal Ellen | Director | AWARD | 10,302 | — | — |
| Jun 16, 2026 | GORMAN KEVIN CHARLES | Director | AWARD | 20,604 | — | — |
| Jun 16, 2026 | GORMAN KEVIN CHARLES | Director | AWARD | 10,302 | — | — |
| Jun 16, 2026 | GUSTAFSON KURT A | Director | AWARD | 20,604 | — | — |
| Jun 16, 2026 | GUSTAFSON KURT A | Director | AWARD | 10,302 | — | — |
| Jun 16, 2026 | Klencke Barbara | Director | AWARD | 20,604 | — | — |
| Jun 16, 2026 | Klencke Barbara | Director | AWARD | 10,302 | — | — |
| Jun 16, 2026 | Montgomery Alan Bruce | Director | AWARD | 20,604 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for XNCR.
Shares short
15,751,444
Settlement Sep 15, 2026
Change vs prior
+5.6%
Semi-monthly cycle
Days to cover
13.2
At avg daily volume
Of shares outstanding
≈21.2%
Estimate — not % of float
All XNCR filing & press-release reports (10)
- 8-K reportAug 6, 2026
- CLUSTER reportJul 8, 2026
- 144 reportJun 15, 2026
- 144 reportJun 15, 2026
- 8-K reportMay 6, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 27, 2026
- CLUSTER reportMar 9, 2026
- 8-K reportMar 4, 2026
- 8-K reportFeb 25, 2026